The Separation Of Sandoz, A Story Years In The Making
Proposed Spin From Novartis Set For 4 October, Following Years Of Conjecture
Novartis’ shareholders last month voted yes on the proposal to separate Sandoz into a standalone generics and biosimilars firm. On the eve of the spin-off, Generics Bulletin looks back at a deal that was seemingly destined to happen sooner rather than later.
